Newsmaker: Dr. Lakshmanan Krishnamurti
Family: Wife, Uma; Sons, Nachiket and Bharat
Education: M.D. from the Armed Forces Medical College, Pune, India, 1980
Background: Dr. Krishnamurti is clinical director of hematology in the Division of Hematology/Oncology at Children's Hospital of Pittsburgh of UPMC. His research has focused on sickle cell disease, a hereditary condition where red blood cells are crescent-shaped, sticky and rigid, causing pain, eventual organ shutdown and reduced life expectancy. While a bone marrow transplant can provide a cure, it requires a long hospital stay and immunosuppressant drugs or chemotherapy.
Notable: Dr. Krishnamurti received a $2 million research award from the Patient-Centered Outcomes Research Institute to develop an online tool for people with sickle cell disease. While several treatments are available for the disease, each carries risks and side effects. Dr. Krishnamurti hopes his project can make it easier for patients to find the treatment that suits their condition and needs.
Quote: “Some people will do anything to cure their disease, others feel like they've lived so long with their disease that they don't want a treatment that has just a chance of a cure... This particular project will provide a web-based tool so that patients and families can decide what's important to them.”
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments â either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.